54 results about "Signaling proteins" patented technology

The invention relates to the technical field of immune cell culture, in particular to an immune cell culture data monitoring method and system based on activation analysis. When the immune cell culture equipment monitors that the signal protein is conducted on the abnormal standard signal channel, the real-time metabolic network is reduced based on the interference degree of the abnormal standard signal channel on the metabolic pathway, the metabolic enzyme concentration is calculated and analyzed, and a metabolic activity monitoring reference is generated; if it is monitored and detected in real time that unreasonable metabolism conditions exist in metabolic data of immune cell culture, peak integral deviation parameters for cell factor compensation are constructed based on the metabolic enzyme concentration deviation value of the metabolic activity monitoring benchmark to conduct injection compensation regulation and control on cell factors of the cultured immune cell sample. According to the method, the abnormal proliferation data, the abnormal proliferation-causing signal path data and the metabolic data in the immune cell culture process can be subjected to rapid and accurate activation analysis, so that the immune cell activation performance can be better optimized, and the culture quality is improved.

The present invention relates to a peptide having an activity of promoting hair growth or preventing or inhibiting hair loss. The peptides of the present invention have the activity of promoting the proliferation of hair follicle dermal papilla cells (HFDPC), activating cell proliferation-related signaling proteins in human dermal papilla cells, activating beta-catenin, improving the expression level of beta-catenin downstream factors, down-regulating the expression level of alopecia protein DKK-1, and increasing the expression of keratin in hair outer root sheath cells (HORSC).

The invention belongs to the technical field of vegetable protein peptide preparation and functional food, and particularly relates to pea oligopeptide with a lipid-lowering function as well as a preparation method and application of the pea oligopeptide. The amino acid sequences of the pea oligopeptide I, the pea oligopeptide II and the pea oligopeptide III are respectively as shown in SEQ ID NO.1-3. Three pea oligopeptides are obtained through enzymolysis separation in pea protein, and tests prove that the three pea oligopeptides not only have the activity of inhibiting HMG-CoA reductase, but also have the effect of inhibiting the activity of liver cancer cells, and meanwhile, have the effect of inhibiting the activity of HMG-CoA reductase. The traditional Chinese medicine composition has an obvious improvement effect on accumulation of lipid in liver cells and an effect of regulating and controlling expression of lipid metabolism related signal protein, so that the effects of reducing blood fat and preventing and / or improving the non-alcoholic fatty liver disease can be achieved.

The present invention relates to a peptide having an activity of promoting hair growth or preventing or inhibiting hair loss. The peptide of the present invention has an activity of promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating a cell proliferation-related signal protein in human dermal papilla cells, activating β-catenin, improving expression levels of factors downstream of β-catenin, down-regulating expression levels of hair-loss protein DKK-1, and increasing expression of keratins in hair outer root sheath cells (HORSC).

The present invention relates to a peptide with the activity of promoting hair growth or preventing or inhibiting alopecia. The peptide of the present invention promotes the proliferation of human follicular dermal papilla cells (HFDPC), activates cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhances the expression levels of beta-catenin downstream genes, down-regulates the expression levels of the hair loss protein DKK-1, increases the expression of keratin proteins in hair outer root sheath cells (HORSC) and up-regulates the expression of transcription factors involved in cell activation in germinal matrix cells (GMC).

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

The present invention relates to biological detection technology, and discloses a biosensor and its application and a method for high-throughput screening of zingerone-producing bacteria. The biosensor contains a first sensing element and a second sensing element, wherein the first sensing element contains α-tubulin and a first signal protein expressed by fusion with the α-tubulin, and the second sensing element contains β-tubulin and a second signal protein expressed by fusion with the β-tubulin; the end of one of the first signal protein and the second signal protein is the N-terminus and the end of the other is the C-terminus, and the first signal protein and the second signal protein can be combined to form a reporter signal. The biosensor can couple zingerone with a fluorescent signal, efficiently and accurately respond to the concentration of zingerone, and realize high-throughput screening of the intracellular product zingerone in microorganisms.

Provided herein is a composition comprising, a cell, comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains. Also provided herein are methods for treating diseases using the compositions described herein. Further provided herein is a kinase inhibitor for use in therapeutic methods described herein.

The invention relates to a signal protein RH1 for promoting phosphorus absorption and growth of plants and application of the signal protein RH1, the amino acid sequence of the signal protein RH1 is shown as SEQ ID NO.1, and the plants include but are not limited to arabidopsis thaliana and oilseed rape.

Engineered synthetic signaling molecules, herein termed "trikines", are provided. Trikines are genetically engineered, tri-specific ligands of cell surface receptors, where the trikine specifically binds at high affinity to the extracellular domains of three different cell surface receptor polypeptides. In some embodiments, generation of a receptor multimer by binding to a trikine results in intracellular trans-phosphorylation of receptor subunits. In some embodiments trikines modulate STAT signaling that results from the receptor binding and mutimerization.

The application discloses application of hybrid two-component signal protein HtsM in regulation of Xanthomonas campestris virulence and motility, and belongs to the technical field of biotechnology. htsM1 、 htsM2 、 htsM3 Single deletion, double deletion, triple deletion mutant and complementary strain and overexpression strain are constructed by constructing Xanthomonas campestris The HtsM1-HtsM2-HtsM3 complex is found to be jointly negatively regulated to Xcc pathogenicity, biofilm synthesis and motility; the pathogenicity, biofilm formation and motility of Xcc are enhanced by simultaneous deletion of the three genes, the complementary strain can be restored to the wild type level, and the overexpression strain can significantly improve the disease resistance. The complex negatively regulates the expression of flagellum synthesis related genes in a broad spectrum, but does not affect the synthesis of traditional virulence factors such as amylase, protease and extracellular polysaccharide. The application clearly defines HtsM as a key negative regulation factor of Xcc pathogenicity and motility, and provides a new target and theoretical basis for prevention and treatment of crucifer black rot.

Provided herein is a transmembrane signaling protein comprising: (a) an extracellular binding domain comprising a scFv having the CDRs of a selected antibody, (b) a transmembrane domain, and (c) an intracellular signaling domain. Cells expressing the same are also provided, as well as methods of treatment that employ the same.

This invention discloses a method for constructing an immune animal model for preparing biofusion enzyme antibodies and its application. The method includes the following steps: designing and screening sgRNAs with high cleavage efficiency based on signal protein genes, and constructing an sgRNA-Cas9 expression vector; linearizing the plasmid by double enzyme digestion, and then ligating it with a signal protein gene fragment containing left and right homologous arms to obtain the Donor plasmid; co-transfecting the sgRNA-Cas9 expression vector and the Donor plasmid into target animal somatic cells, and screening to obtain positive somatic cells that stably integrate the target gene; using the positive somatic cells as nuclear donors for nuclear transfer to construct recombinant embryos, and transferring the recombinant embryos into recipient female animals; after delivery, identifying transgenic animal individuals carrying biofusion enzyme antibodies by genomic PCR. Based on this transgenic animal model, different target antibodies with clinical value can be developed.

The invention belongs to the technical field of gene engineering, and particularly relates to a light-controlled yeast two-hybrid system as well as an establishment method and application thereof. The light-controlled yeast two-hybrid system is obtained by integrating a phycocyanobilin synthesis module into a yeast strain containing a reporter gene and then transferring into a phytochrome A-LexA fusion expression vector and an AD-FHY1 fusion expression vector. The light-controlled yeast two-hybrid system provided by the invention well overcomes the defects that the existing light-controlled yeast two-hybrid system needs exogenous application of phycocyanobilin, the operation is more complex and the cost is higher, and does not cause that the phytochrome apoprotein expressed in yeast cells cannot realize conversion of two conformational forms of Pfr / Pr; and finally, the difference between the interaction intensity of the phytochrome in two conformational forms and the FHY1 signal protein cannot be distinguished.

The present invention discloses a combination probe for detecting Aeromonas bacteria and its application. The Aeromonas bacteria detection combination probe of the present invention comprises an analytical probe, a capture probe, and a signal probe. The analytical probe specifically binds to the rRNA of Aeromonas bacteria; the capture probe is connected to a carrier and specifically binds to one end of the analytical probe; and the signal probe is provided with a signal protein marker and specifically binds to the other end of the analytical probe. The Aeromonas detection combination probe of the present invention is cleverly designed and can rapidly detect Aeromonas bacteria qualitatively and quantitatively. The detection method is simple to operate, has good reproducibility, and is suitable for large-scale promotion and application.

Biodegradable particles for interacting with immune cells to generate an immunosuppressive effect are disclosed. The biodegradable particle comprises a polyester or polyester blend with at least one soluble protein or small molecule encapsulated within the particle and at least two types of protein attached to a surface of the particle or to a coating on the surface thereof, which can be used to induce targeting regulatory T cells (Tregs). The at least two types of protein attached to a surface of the particle or to a coating on the surface thereof include a “Signal 1” protein that binds to an immune cell and a “Signal 2” protein that acts as a co-stimulatory molecule to immune cells. The encapsulated protein can be an interleukin and / or a cytokine. Methods of their use for treating a disease or condition, including an autoimmune disease, are disclosed.

The present disclosure relates to methods of treating pancreatic cancer. In particular, methods of treating pancreatic cancer and limiting overexpression of oncogenes, activating tumor suppressor genes, or modulating signaling proteins in a patient are described, comprising administering a compound and a pharmaceutical combination as described herein.

The invention provides application of a compound inhibitor targeting a G protein coupled receptor ADGRE1, the compound inhibitor is called ADGRE1-i for short, and the molecular formula of the compound inhibitor is C27H22ClN3O3. According to the application, ADGRE1-i is applied to preparation of drugs for treating diseases caused by high expression of ADGRE1, the diseases caused by high expression of ADGRE1 comprise leukemia, and the leukemia comprises acute leukemia, chronic leukemia, hair cell leukemia and juvenile lymphocytic leukemia. The ADGRE1-i inhibits the activation of the ADGRE1 protein and the activation of downstream signal protein through the combination of the targeting interference ligand and the ADGRE1 protein, inhibits the proliferation of leukemia cells, and significantly inhibits the proliferation of AML cells.

This invention relates to peptides with activity that promotes hair growth or prevents or inhibits hair loss. The peptides of this invention promote the proliferation of human follicular dermal papilla cells (HFDPC), activate cell proliferation-related signaling proteins and β-catenin in HFDPC, enhance the expression levels of downstream genes of β-catenin, downregulate the expression level of the hair loss protein DKK-1, increase the expression of keratin in hair follicle outer root sheath cells (HORSC), and upregulate the expression of transcription factors involved in cell activation in germinal stromal cells (GMC).

The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.

Compositions, systems, methods, etc., comprising medically-acceptable fucans configured to be effective for medical treatments, post-surgical treatments, disease inhibition, etc., wherein signaling protein activity contributes to the initiation, progression, severity, prognosis etc., of such medical conditions. In some embodiments, such treatments comprise the medically-acceptable fucans inhibiting or sequestering such signaling proteins. Signaling proteins include proteins such as cytokines and chemokines.

This invention relates to the field of biopharmaceuticals, and in particular to an Fc signaling protein and its uses. The Fc signaling protein is the Fc segment of an engineered IgG antibody or an engineered FcγRIIA. The engineered IgG antibody's Fc segment is obtained by mutating the Fc segment of a wild-type IgG antibody. When the engineered IgG antibody's Fc segment binds to FcγRIIA, the reverse bond interaction is stronger than when the wild-type FcγRIIA binds to the Fc segment of the IgG antibody. Similarly, the engineered FcγRIIA, obtained by mutating wild-type FcγRIIA, also exhibits a stronger reverse bond interaction when binding to the Fc segment of an IgG antibody than when the wild-type FcγRIIA binds to the Fc segment of the IgG antibody.

The present invention belongs to the field of pharmaceutical formulations. Specifically disclosed are a nanodrug for synergistically removing fibrosis and inhibiting pancreatic cancer metastasis and a preparation method therefor. By means of the self-assembly of a small-molecule prodrug, excipient-related toxicity is avoided, and a high drug loading rate is achieved. By means of hybrid membrane encapsulation, homologous targeting of fibrotic adhesion interstitium and receptor protein-mediated active targeting are achieved. By means of the response of the prodrug molecule to ROS, massive, rapid, and traceless drug release is achieved in the fibrotic adhesion interstitium, removing the self-limiting characteristic of the release of a responsive small-molecule drug. The released drugs Cap and CA can simultaneously inhibit fibrosis signals / proteins, synergistically removing fibrosis. As the removal of fibrosis progresses, Cap and CA released rapidly and tracelessly in pancreatic cancer cells can simultaneously inhibit the metastasis / invasion signaling pathway of pancreatic cancer cells, synergistically inhibiting metastasis. The dynamic synergy between the process of removing fibrosis and the process of inhibiting metastasis provides a new approach for removing fibrosis in the treatment of pancreatic cancer.

The invention discloses a Napsin A biological fusion enzyme antibody with a signal protein tag and application, an amino acid sequence of a light chain variable region of an anti-human Napsin A antibody is shown as SEQ ID NO: 7, an amino acid sequence of a heavy chain variable region of the anti-human Napsin A antibody is shown as SEQ ID NO: 3, the signal protein tag HRP is inserted into the N end of a light chain of the anti-human Napsin A antibody, and the amino acid sequence of the light chain variable region of the obtained HRP-Napsin A antibody is shown as SEQ ID NO: 5. In addition, the invention also provides a preparation method of the HRP-Napsin A antibody, the HRP-Napsin A antibody is a molecule completely secreted along with the antibody, has no heterogeneity, is good in sensitivity, high in specificity and stable in performance, and does not need to add a secondary antibody during detection, so that the cost is saved, and the efficiency is improved.

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

The invention belongs to the technical field of biocontrol microorganism genetic engineering, and particularly relates to an sfgA gene for regulating and controlling growth and development of beauveria bassiana and application of the sfgA gene. The invention discloses an sfgA gene for regulating and controlling growth and development of beauveria bassiana, the nucleotide sequence of the sfgA gene is as shown in SEQ ID NO.1, and the amino acid sequence of encoded protein of the sfgA gene is as shown in SEQ ID NO.2. By systematically researching the effect of the development signal protein sfgA in the asexual spore production process of the beauveria bassiana and the regulation and control mechanism of the development signal protein sfgA, the growth and development of the beauveria bassiana can be regulated and controlled. A theoretical basis is laid for researching a filamentous fungus asexual sporulation molecular mechanism, and a new scientific basis and gene resources are provided for mining and genetic improvement of biocontrol potentials of biocontrol fungi.

This invention relates to the field of *Paenibacillus polymyxa*, addressing the problem of low production of immune signaling proteins in existing *Paenibacillus* strains. It provides a new *Paenibacillus polymyxa* strain, deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC NO.36323. This invention provides a novel *Paenibacillus* strain that possesses both high production of immune signaling proteins and natural biocontrol and growth-promoting properties. It can secrete polymyxin-like antibacterial substances and simultaneously synthesize PR proteins and selenomethionine, overcoming the limitations of traditional *Paenibacillus* strains that only inhibit bacterial growth and lack immune signal transduction. The preparation method provided by this invention involves the strain converting sodium selenite into nano-selenium, which combines with the secreted PR protein to form nano-selenoprotein. Simultaneously, it synergistically produces polymyxins, achieving a dual effect of immune signal activation and direct bacterial inhibition, solving the problems of weak signaling and lack of synergistic antibacterial effects of traditional inducers.

The invention relates to a peptide capable of promoting hair growth and preventing and inhibiting alopecia and application thereof. The peptide provided by the invention has the following activities: promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhancing the expression level of growth factor-related genes, enhancing the expression level of beta-catenin downstream genes, reducing the expression level of alopecia protein DKK-1, and promoting the growth of the hair follicle dermal papilla cells. Increasing the expression of keratin in hair outer root sheath cells (HORSC), and increasing the expression of transcription factors involved in cell activation in hair growth stromal cells (GMC); and promoting differentiation of hair follicle stem cells (HFSC).

Described herein are methods for treating insulin-dependent diabetes in a subject, Donohue syndrome, Rabson–Mendenhall syndrome, or a disorder associated with obesity, preferably diabetes, metabolic syndrome, fatty liver disease, nonalcoholic steatohepatitis (NASH), non-hepatic steatosis, obesity-associated cardiac hypertrophy, or dyslipidemia, the method comprising administering a therapeutically effective amount of adipose-secreted signaling protein (ADISSP) polypeptide to a subject in need thereof. In some embodiments, the polypeptide is administered in a dose of 0.5-2.5 mg / kg / day, e.g., 1.0-1.4 mg / kg per day once a day or once every other day.

This invention relates to the fields of biotechnology and medicine, and particularly to nucleic acid aptamers, biosensors, and their applications. The invention provides nucleic acid aptamers having nucleotide sequences as shown in any of SEQ ID NO:1 to SEQ ID NO:14. The invention utilizes in vitro screening technology to screen nucleic acid aptamers, ultimately obtaining nucleic acid aptamers that target and bind to the ADAR1 protein. Subsequently, based on the nucleic acid aptamers as target protein recognition elements, a dual-signal protein biosensor with input and output signals is constructed, enabling in vitro detection of target proteins and imaging of native proteins in live cells. Finally, the imaging technology is applied to drug evaluation and screening of proteins.